Embecta Corp. (EMBC) recently announced the receipt of 510(k) clearance from the FDA for its proprietary disposable patch pump for insulin delivery. This development marks a critical step forward in diabetes care, particularly for individuals with Type 2 diabetes (T2D). With a focus on addressing the specific needs of T2D patients, this system represents a notable advancement in insulin delivery technology. The clearance of this insulin delivery system is expected to significantly enhance Embecta's market p ...